Genome-wide association study reveals targets for COVID-19 treatments
The study found five key genetic differences when they compared sequences from severe COVID-19 patients to healthy individuals.
List view / Grid view
The study found five key genetic differences when they compared sequences from severe COVID-19 patients to healthy individuals.
Two new studies suggest that SARS-CoV-2-specific IgA antibodies are more neutralising and therefore COVID-19 vaccines should encourage an IgA response.
A new study has identified the mechanisms through which the SARS-CoV-2 virus enters the brain and how the immune system responds once it does.
Researchers have found a way to systematically extract various cell types from induced pluripotent stem cells and made their transcription factor source accessible for other scientists.
Researchers reveal how two genetic variations may contribute to COVID-19 disease severity and suggest the product of one, the CD209 antigen, may be a potential drug target.
Researchers have shown that 70 percent of Alzheimer’s patients have high levels of proteins associated with dysfunction in the endosomal trafficking system in their spinal fluid.
The first comprehensive survey of genomics, transcriptomics, global proteomics and phosphoproteomics has revealed insights into paediatric brain tumours.
Researchers used integrative network biology analysis to identify the molecular mechanisms that may drive Alzheimer’s and identified a potential therapeutic intervention.
The study shows how drug-like small molecules inhibit the activity of Transient Receptor Potential Canonical 1/4/5 (TRPC1/4/5) channels and could transform the development of future therapies.
Scientists have shown how SARS-CoV-2 induces changes in the architecture of host cells to drive replication and made their data available to all.
Scientists suggest the PCSK9Q152H gene variant may act as a “fountain of youth”, allowing people to live longer, healthier lives.
The non-human primate model exhibited a COVID-19-like disease and showed how symptoms and viral activity change over the course of SARS-CoV-2 infection.
A specific furin cleavage motif on the SARS-CoV-2 Spike protein, not present on other coronaviruses (CoVs), could be targeted by novel COVID-19 therapies.
The semi-automated process enabled researchers to make retinal organoid production and selection nearly four times faster.
According to a new study, the SARS-CoV-2 virus is accumulating genetic mutations, including one called D614G which may have made it more contagious.